Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsBlue Cross Blue Shield SC formulary Prior Auth | O…
    Ask Trek AI about this page
    CurrentBlue Cross Blue Shield - South CarolinaPolicy N/A

    Formulary step therapy and prior authorization criteria for selected outpatient drugs

    Customize your policy alerts

    Sign up for all Blue Cross Blue Shield - South Carolina policy alerts

    Know when Blue Cross Blue Shield - South Carolina releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines step-therapy and trial-of-therapy requirements for specific outpatient pharmacy products (Formulary ID 25385); affects pharmacy providers and prescribers requesting coverage for the listed drugs and titration packs.

    Policy Summary
    PayerBlue Cross Blue Shield - South Carolina
    PolicyFormulary step therapy and prior authorization criteria for selected outpatient drugs
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateNov 1, 2025
    Last ReviewOct 1, 2025
    Next Review DateN/A
    Key ActionObtain and document required trials of specified generic comparators (two generics for Exxua and Fanapt; specific comparator trials for Invega Hafyera, Relistor, and Zonisade) when submitting prior authorization.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    11+

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    drugs or titration packs listed
    25385formulary identifier
    11/01/2025effective date
    10/01/2025last updated

    Coverage Criteria for Formulary Products

    Exxua / Exxua Titration Pack

    Covered when ALL of the following are met

    Exxua initial: Trial of two generics from the listed antidepressant agents (bupropion; mirtazapine; citalopram [tablet or solution]; desvenlafaxine succinate ER; duloxetine; escitalopram; fluoxetine; fluvoxamine; paroxetine; sertraline [tablet or solution]; venlafaxine hydrochloride)2 agents

    Approve for continuation of prior therapy

    Fanapt and Titration Packs A/B/C

    Covered when ALL of the following are met

    Fanapt initial: Trial of two of the following oral generic formulary atypical antipsychotic agents: asenapine; aripiprazole; olanzapine; paliperidone; quetiapine; risperidone; ziprasidone2 agents

    Approve for continuation of prior therapy

    Invega Hafyera

    Covered when ALL of the following are met (new starts only)

    Invega Hafyera initial: Trial of one of the following: Invega Sustenna or Invega Trinza1 agent

    Step applies to new starts only. Approve for continuation of prior therapy

    Relistor

    Covered when ALL of the following are met

    Relistor initial: Trial of lubiprostone, Constulose, Enulose, Generlac, or lactulose1 agent

    Zonisade

    Covered when ALL of the following are met (new starts only)

    Zonisade initial: Trial of generic zonisamide capsule1 agent

    Step applies to new starts only. Approve for continuation of prior therapy

    The source document contains an entry for Diclofenac Sodium GEL 3% but does not list any explicit exclusion conditions for the products included in this formulary. No product-specific exclusion language or patient-population exclusions are provided in the document.

    The document does not include any statements labeling treatments as not medically necessary. There are no explicit 'not medically necessary' determinations or language present for the listed products.

    Product Coding and Identifiers

    Products listed without codesmixed
    NDC/HCPCS not specifiedDiclofenac Sodium GEL 3% listed as product affected; no explicit codes in document
    Other listed productsmixed
    N/AAuvelity, Emsam, Exxua, Fanapt, Fanapt Titration Packs A/B, Invega Hafyera, Relistor, Zonisade and associated titration packs are listed; no billing codes provided in document

    Prior Authorization, Documentation, and Denial Risks

    Prior Authorization

    Exxua / Exxua Titration Pack — Prior Authorization

    Prior Authorization requires documentation of trials (and lack of response or intolerance) of two generics from the listed antidepressant agents for Exxua or its titration pack. Approve for continuation of prior therapy.

    • Affected products: Exxua, Exxua Titration Pack
    • Required generics: bupropion, mirtazapine, citalopram (tablet or solution), desvenlafaxine succinate ER, duloxetine, escitalopram, fluoxetine, fluvoxamine, paroxetine, sertraline (tablet or solution), venlafaxine hydrochloride
    Prior Authorization

    Fanapt and Titration Packs — Prior Authorization

    Prior Authorization requires trial of two of the listed oral generic atypical antipsychotics. Approve for continuation of prior therapy.

    • Affected products: Fanapt, Fanapt Titration Pack, Lybalvi, Secuado
    • Required generics: asenapine, aripiprazole, olanzapine, paliperidone, quetiapine, risperidone, ziprasidone

    Background and Scope

    This formulary organizes step-therapy and trial requirements for several outpatient medications, including neuropsychiatric agents. It specifies required trials of lower-cost or generic alternatives before certain branded or specialty products are approved, and generally permits continuation of prior therapy where indicated.

    Definitions and Key Terms

    Exxua / Exxua Titration Pack — Required trials
    RequirementTrial and documented failure or intolerance of two generic antidepressant agents from the listed formulary products (bupropion; mirtazapine; citalopram tablet or solution; desvenlafaxine succinate ER; duloxetine; escitalopram; fluoxetine; fluvoxamine; paroxetine; sertraline tablet or solution; venlafaxine hydrochloride).
    Approval for continuationContinuation of prior Exxua or Exxua Titration Pack therapy is approved without requiring the two-agent trial.
    Threshold2 agents must be trialed and documented as failed or not tolerated.
    Documentation requiredClinical records must document trials and lack of response or intolerance for the two generic agents listed.
    Fanapt and Titration Packs — Required trials
    Requirement

    Initial Therapy Requirements

    Exxua initial therapy

    Exxua initial: Trial of two generics from the listed antidepressant agents (bupropion; mirtazapine; citalopram [tablet or solution]; desvenlafaxine succinate ER; duloxetine; escitalopram; fluoxetine; fluvoxamine; paroxetine; sertraline [tablet or solution]; venlafaxine hydrochloride)2 agents

    Fanapt initial therapy

    Fanapt initial: Trial of two listed oral generic atypical antipsychotics (asenapine; aripiprazole; olanzapine; paliperidone; quetiapine; risperidone; ziprasidone)2 agents

    Invega Hafyera initial therapy

    Continuation Therapy Requirements

    Exxua continuation

    Exxua continuation: Continuation of prior Exxua therapy is approved

    Fanapt continuation

    Fanapt continuation: Continuation of prior Fanapt therapy is approved

    Invega Hafyera continuation

    Invega Hafyera continuation: Continuation of prior Invega Hafyera therapy is approved

    Zonisade continuation

    Step Therapy Rules

    Step therapy requirementApplicability
    Trial of one of the following: Invega Sustenna or Invega TrinzaStep applies to new starts only
    Approve for continuation of prior therapy
    Step therapy requirementApplicability
    Trial of generic zonisamide capsuleStep applies to new starts only
    Approve for continuation of prior therapy
    ProductRequired trial(s) prior to approval
    Exxua / Exxua Titration PackTrial of two generics from the following formulary antidepressant agents: bupropion; mirtazapine; citalopram (tablet or solution); desvenlafaxine succinate ER; duloxetine; escitalopram; fluoxetine; fluvoxamine; paroxetine; sertraline (tablet or solution); venlafaxine hydrochloride
    Fanapt and Titration PacksTrial of two of the following oral generic formulary atypical antipsychotic agents: asenapine; aripiprazole; olanzapine; paliperidone; quetiapine; risperidone; ziprasidone
    Policy Summary
    PayerBlue Cross Blue Shield - South Carolina
    PolicyFormulary step therapy and prior authorization criteria for selected outpatient drugs
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateNov 1, 2025
    Last ReviewOct 1, 2025
    Next Review DateN/A
    Key ActionObtain and document required trials of specified generic comparators (two generics for Exxua and Fanapt; specific comparator trials for Invega Hafyera, Relistor, and Zonisade) when submitting prior authorization.
    SourceLink
    On This Page
    Coverage Criteria for Formulary ProductsProduct Coding and IdentifiersPrior Authorization, Documentation, and Denial RisksBackground and ScopeDefinitions and Key TermsInitial Therapy RequirementsContinuation Therapy RequirementsStep Therapy Rules
    Step Therapy

    Invega Hafyera — Prior Authorization and Step Therapy

    Prior Authorization requires trial of Invega Sustenna or Invega Trinza for new starts of Invega Hafyera; this step applies to new starts only. Continuation of prior therapy is approved. Failure to document a trial of Invega Sustenna or Invega Trinza for a new start may result in denial.

    • Applies to new starts of Invega Hafyera only
    • Continuation of prior therapy is permitted without the step
    Prior Authorization

    Relistor — Prior Authorization

    Prior Authorization requires documentation of a trial of lubiprostone, Constulose, Enulose, Generlac, or lactulose prior to approval of Relistor. Failure to document such a trial may trigger denial.

    • Affected product: Relistor
    • Required trial agents: lubiprostone, Constulose, Enulose, Generlac, lactulose
    Step Therapy

    Zonisade — Prior Authorization and Step Therapy

    Prior Authorization requires trial of a generic zonisamide capsule for new starts of Zonisade; this step applies to new starts only. Continuation of prior therapy is approved. Failure to document a trial of generic zonisamide capsule for a new start may trigger denial.

    • Applies to new starts of Zonisade only
    • Continuation of prior therapy is permitted without the step
    Documentation Required

    Documentation Requirement — Trials and Rationale

    Documentation requirement: For all applicable step or prior authorization rules above, provide records showing trials and lack of response or intolerance (or other clinical rationale) for the required prior agents. Failure to provide required documentation may result in denial of the request.

    • Include dates, agent names, doses, duration, and reason for discontinuation (lack of efficacy or intolerance)
    Denial Risk

    Denial Risk — Missing Required Documentation

    Denial risk: Failure to document required prior trials as specified for Exxua, Fanapt (and titration packs), Invega Hafyera (new starts), Relistor, or Zonisade (new starts) may result in denial of authorization.

    • Exxua/Exxua Titration Pack — missing documentation of two generic antidepressant trials
    • Fanapt/Fanapt Titration Pack — missing documentation of two generic atypical antipsychotic trials
    • Invega Hafyera (new starts) — missing documentation of trial of Invega Sustenna or Invega Trinza
    • Relistor — missing documentation of trial of lubiprostone, Constulose, Enulose, Generlac, or lactulose
    • Zonisade (new starts) — missing documentation of trial of generic zonisamide capsule
    Trial and documented failure or intolerance of two oral generic formulary atypical antipsychotics from the following: asenapine; aripiprazole; olanzapine; paliperidone; quetiapine; risperidone; ziprasidone.
    Approval for continuationContinuation of prior Fanapt or Fanapt titration pack therapy is approved without requiring the two-agent trial.
    Threshold2 agents must be trialed and documented as failed or not tolerated.
    Documentation requiredClinical records must document trials and lack of response or intolerance for the two generic atypical antipsychotics listed.
    Invega Hafyera initial: Trial of Invega Sustenna or Invega Trinza (new starts only)1 agent

    Relistor initial therapy

    Relistor initial: Trial of lubiprostone, Constulose, Enulose, Generlac, or lactulose1 agent

    Zonisade initial therapy

    Zonisade initial: Trial of generic zonisamide capsule (new starts only)1 agent
    Zonisade continuation: Continuation of prior Zonisade therapy is approved